{"id":"W4283072502","doi":"10.1016/j.annonc.2022.04.062","title":"44TiP ENGOT-ov65/KEYNOTE-B96: Phase III, randomized, double-blind study of pembrolizumab vs placebo + paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Pembrolizumab; Bevacizumab; Ovarian cancer; Paclitaxel; Oncology; Placebo; Internal medicine; Double blind; Chemotherapy; Cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001571623,0.001954635,0.002816238,0.0006146506,0.0005367987,0.001308952,0.001175524,0.002035479,0.01418135],"category_scores_gemma":[0.001417144,0.00103363,0.001831396,0.0004861861,0.001292899,0.001461392,0.0004386019,0.004846704,0.002176814],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007595331,"about_ca_system_score_gemma":0.001377362,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001366182,"about_ca_topic_score_gemma":0.002917202,"domain_scores_codex":[0.9994979,0.0002205192,0.00003377472,0.00009945752,0.00003716101,0.000111228],"domain_scores_gemma":[0.9994246,0.0001285817,0.00009695986,0.00005616639,0.0000299171,0.0002638361],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9619221,0.009709589,0.0002397988,0.0006626664,0.0007861512,0.00002511377,0.00003406537,0.0003398968,0.00453065,0.0001603488,0.001121691,0.02046797],"study_design_scores_gemma":[0.9559581,0.04195638,0.0005721584,0.00001948523,0.0002192444,0.00001362879,0.00001022275,0.0002390463,0.000427346,0.0000778935,0.0004951134,0.00001139735],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9716917,0.006785409,0.001763243,0.001168943,0.00144498,0.007665791,0.002941928,0.0006894009,0.005848518],"genre_scores_gemma":[0.9727758,0.00384418,0.003361898,0.001668111,0.0005772837,0.006226117,0.001897888,0.00009281024,0.009555999],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01418135,"threshold_uncertainty_score":0.0474413,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1193212526315547,"score_gpt":0.4276021041533365,"score_spread":0.3082808515217819,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}